HIF activation causes synthetic lethality between the tumor suppressor and the histone methyltransferase.

TitleHIF activation causes synthetic lethality between the tumor suppressor and the histone methyltransferase.
Publication TypeJournal Article
Year of Publication2017
AuthorsChakraborty AA, Nakamura E, Qi J, Creech A, Jaffe JD, Paulk J, Novak JS, Nagulapalli K, McBrayer SK, Cowley GS, Pineda J, Song J, Wang YE, Carr SA, Root DE, Signoretti S, Bradner JE, Kaelin WG
JournalSci Transl Med
Volume9
Issue398
Date Published2017 07 12
ISSN1946-6242
KeywordsAmino Acid Sequence, Biomarkers, Tumor, Carcinoma, Renal Cell, Cell Line, Tumor, Cell Proliferation, CRISPR-Cas Systems, Histones, Humans, Hypoxia-Inducible Factor 1, alpha Subunit, Kidney Neoplasms, Polycomb Repressive Complex 2, Synthetic Lethal Mutations, Transcription, Genetic, Von Hippel-Lindau Tumor Suppressor Protein
Abstract

Inactivation of the von Hippel-Lindau tumor suppressor protein (pVHL) is the signature lesion in the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC). pVHL loss causes the transcriptional activation of hypoxia-inducible factor (HIF) target genes, including many genes that encode histone lysine demethylases. Moreover, chromatin regulators are frequently mutated in this disease. We found that ccRCC displays increased H3K27 acetylation and a shift toward mono- or unmethylated H3K27 caused by an HIF-dependent increase in H3K27 demethylase activity. Using a focused short hairpin RNA library, as well as CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) and a pharmacological inhibitor, we discovered that pVHL-defective ccRCC cells are hyperdependent on the H3K27 methyltransferase EZH1 for survival. Therefore, targeting EZH1 could be therapeutically useful in ccRCC.

DOI10.1126/scitranslmed.aal5272
Alternate JournalSci Transl Med
PubMed ID28701475
PubMed Central IDPMC6039096
Grant ListR01 CA068490 / CA / NCI NIH HHS / United States
P50 CA101942 / CA / NCI NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States
R35 CA210068 / CA / NCI NIH HHS / United States
T32 CA009361 / CA / NCI NIH HHS / United States